TCTR20221114001尚未招募不适用
Pharmacokinetics and Therapeutic Drug Monitoring of Intravenous Sulbactam in Pediatrics
Ratchadapisek Sompoch Research Fund0 个研究点目标入组 62 人开始时间: 2022年11月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 1 Months 至 18 Years（—）
- 性别
- All
入选标准
- •1. Inclusion criteria (for therapeutic drug monitoring)
- •1.1 Patients aged from 1 month to 18 years at the day of enrollment.
- •1.2 Body weight from 3 kg.
- •1.3 Receiving intravenous sulbactam for the treatment of proven or suspected A. baumannii infections.
- •1.4 Adequate vascular access to enable blood collection
- •2. Inclusion criteria (for the pharmacokinetic drug study)
- •2.1 Patients aged from 1-12 years at the day of enrollment.
- •2.2 Body weight from 10 kg.
- •2.3 Receiving intravenous sulbactam for the treatment of proven or suspected A. baumannii infections.
- •2.4 Adequate vascular access to enable blood collection.
排除标准
- •1. Estimated glomerular filtration rate of less than 30 mL/min/1.73 m2, which requires sulbactam dose adjustment.
- •2. Receiving any renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO)
- •3. Beta-lactams or sulbactam allergy
研究者
相似试验
已完成
不适用
Assessment of pharmacokinetics and pharmacokinetic drug-drug interaction with ketoconazole of the metabolite S 41015 after single oral unlabelled microdoses of S 41015 and i.v. radiolabelled microdoses of [14C]-S 41015, and pharmacokinetics of S 38844 after single oral unlabelled microdose of S 38844 and i.v. radiolabelled microdose of [14C]-S 38844 in healthy male participantshart- en vaatziektencardiovascular diseasesNL-OMON38625Institut de Recherches Internationales Servier I.R.I.S6
已完成
4 期
Farmacokinetics and farmacodynamics of drugs used in neonates and children during Extracorporal Membanous Oxygenation (ECMO)patienten aan ECMOheart-lung machineNL-OMON30690Erasmus MC, Universitair Medisch Centrum Rotterdam100
已完成
不适用
Analysis of pharmacokinetics and pharmacodynamics for capecitabine during new chemotherapy regimen by bevacizumab (Bev) in combination with XELOX in unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000013038Tsukasa Hotta10
尚未招募
不适用
A study on the pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanilKCT0007066Inje University Busan Paik Hospital15
进行中（未招募）
1 期
study of the pharmacokinetics and pharmacodynamics of desmopressin oral lyophilisate - route of administration in the pediatric patient population - SAFEPEDRUGEUCTR2014-005200-13-BEGhent University24